Glutathione levels in human tumors.
This review summarizes clinical studies in which glutathione was measured in tumor tissue from patients with brain, breast, gastrointestinal, gynecological, head and neck and lung cancer. Glutathione tends to be elevated in breast, ovarian, head and neck, and lung cancer and lower in brain and liver tumors compared to disease-free tissue. Cervical, colorectal, gastric, and esophageal cancers show both higher and lower levels of tumor glutathione. Some studies show an inverse relationship between patient survival and tumor glutathione. Based on this survey, we recommend approaches that may improve the clinical value of glutathione as a biomarker.
UNC/NCSU Joint Department of Biomedical Engineering, Raleigh, NC 27695-7115, USA. mgamcsi@ncsu.edu
Michael P
MP
Gamcsik
Mohit S
MS
Kasibhatla
Stephanie D
SD
Teeter
O Michael
OM
Colvin
D014408:Biomarkers, Tumor / Q000378:metabolism*; D001932:Brain Neoplasms / Q000378:metabolism / Q000473:pathology; D001943:Breast Neoplasms / Q000378:metabolism / Q000473:pathology; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000378:metabolism / Q000473:pathology; D005978:Glutathione / Q000378:metabolism*; D006258:Head and Neck Neoplasms / Q000378:metabolism / Q000473:pathology; D006801:Humans; D008175:Lung Neoplasms / Q000378:metabolism / Q000473:pathology; D009367:Neoplasm Staging; D009369:Neoplasms / Q000378:metabolism* / Q000473:pathology; D010051:Ovarian Neoplasms / Q000378:metabolism / Q000473:pathology
D014408:Biomarkers, Tumor; D005978:Glutathione